Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America). Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation. 3968

Member's Comments

No comment yet.

Related content which might interest you: Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 618s Year: 2004 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010